Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $36.00

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) had its price target upped by research analysts at Robert W. Baird from $28.00 to $36.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a "neutral" rating on the medical device company's stock. Robert W. Baird's price objective points to a potential downside of 19.50% from the company's previous close.

A number of other equities analysts have also recently issued reports on the stock. Stifel Nicolaus lifted their target price on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, April 23rd. Leerink Partnrs raised Tandem Diabetes Care from a "market perform" rating to an "outperform" rating in a research note on Thursday, April 25th. SVB Leerink raised Tandem Diabetes Care from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $34.00 to $45.00 in a research report on Thursday, April 25th. Wells Fargo & Company upgraded Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $21.00 to $45.00 in a research report on Monday. Finally, StockNews.com upgraded Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research report on Friday, April 19th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $43.45.

Tandem Diabetes Care Price Performance

TNDM stock traded up $8.16 during trading on Friday, reaching $44.72. 5,986,907 shares of the company were exchanged, compared to its average volume of 1,773,321. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The stock's 50 day moving average price is $32.29 and its 200 day moving average price is $26.08. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $47.00. The company has a market cap of $2.89 billion, a P/E ratio of -13.00 and a beta of 1.10.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million for the quarter, compared to analysts' expectations of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. As a group, analysts predict that Tandem Diabetes Care will post -1.62 earnings per share for the current fiscal year.

Institutional Trading of Tandem Diabetes Care

Several institutional investors have recently made changes to their positions in the stock. RiverPark Advisors LLC boosted its holdings in Tandem Diabetes Care by 1,008.4% in the first quarter. RiverPark Advisors LLC now owns 10,153 shares of the medical device company's stock valued at $360,000 after acquiring an additional 9,237 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Tandem Diabetes Care by 98.1% in the 1st quarter. Jennison Associates LLC now owns 2,556,124 shares of the medical device company's stock worth $90,512,000 after purchasing an additional 1,265,534 shares during the period. Capstone Investment Advisors LLC lifted its stake in shares of Tandem Diabetes Care by 63.7% in the 1st quarter. Capstone Investment Advisors LLC now owns 13,585 shares of the medical device company's stock valued at $481,000 after purchasing an additional 5,288 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Tandem Diabetes Care by 4.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 34,506 shares of the medical device company's stock worth $1,222,000 after purchasing an additional 1,493 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Tandem Diabetes Care by 1,481.5% during the 1st quarter. BNP Paribas Financial Markets now owns 145,812 shares of the medical device company's stock worth $5,163,000 after purchasing an additional 136,592 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.